Amylyx Pharmaceuticals (NASDAQ: AMLX) Shares Surged Approximately 48.6% Over the Week to $35.11 (Near the 52-Week High of $35.39, Up Roughly 349% Year-Over-Year) on Volume Exceeding 23.6 Million Shares Monday August 18 (the Stock's Best Day in Nearly Four Years) Following the LUCIDITY Phase 3 Primary Endpoint Hit for Avexitide (55% Reduction in Composite Level 2 and Level 3 Hypoglycemic Events, P=0.000003) in Post-Bariatric Hypoglycemia; The Company Concurrently Priced a $350 Million Underwritten Public Offering of Common Stock to Fund Avexitide Commercial Launch Preparation, NDA Submission Activities, and Broader Pipeline Advancement; Analyst Price Target Lifts Landed Broadly With Guggenheim to $55 From $40 (Buy), Mizuho to $30 From $24 (Outperform), and H.C. Wainwright to $20 From $16; Seeking Alpha Upgraded Coverage to Strong Buy
Amylyx Pharmaceuticals (NASDAQ: AMLX) shares surged approximately 48.6% over the week to $35.11 (near the 52-week high of $35.39, up roughly 349% year-over-year) on volume exceeding 23.6 million shares Monday August 18, 2026, the stock's best day in nearly four years. The rally followed Monday's LUCIDITY Phase 3 primary endpoint hit for avexitide (exendin 9-39, a peptide GLP-1 receptor antagonist administered as 90 mg once-daily subcutaneous injection) documenting a 55% reduction in the composite of Level 2 and Level 3 hypoglycemic events versus placebo (p=0.000003) in post-bariatric hypoglycemia. Amylyx concurrently priced a $350 million underwritten public offering of common stock. Use of proceeds: avexitide commercial launch preparation (Q4 2026 NDA submission, potential 2027 launch if approved), NDA submission activities, broader pipeline advancement including AMX0318 IND-enabling studies, and general corporate purposes. The offering adds immediate dilution risk to the extended rally but positions Amylyx for the multi-quarter launch execution ahead. Analyst price target lifts: Guggenheim raised to $55 from $40 while maintaining Buy; Mizuho analyst Graig Suvannavejh raised to $30 from $24 while maintaining Outperform; H.C. Wainwright raised to $20 from $16. Seeking Alpha upgraded coverage to Strong Buy citing LUCIDITY outcome, avexitide commercial trajectory, and additional 2026 catalysts. The re-rating pattern is typical for first-in-class Phase 3 wins in serious rare-disease indications with no currently approved competitor.